source
- Sling banks $123M for an experimental thyroid eye disease pillA confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.BioPharma Dive · 1mo ago↗ source
- FDA approves first generic radioligand therapy for neuroendocrine tumors as Sionna announces major layoffsThe U.S. Food and Drug Administration has cleared Bexlutry, the first generic version of Novartis’ Lutathera, marking the debut of a radioligand therapy that can be used for SSTR‑positive neuroendo…